Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Cell. 2020 Oct 1;183(2):363–376.e13. doi: 10.1016/j.cell.2020.09.001

Figure 4: Multiparameter Bayesian frameworks for noninvasive outcome classification.

Figure 4:

A) Schematic depicting the discovery and validation approach for generating and testing the DIREct models.

B) Patient characteristics. Each column represents an individual patient. Tumor histology, smoking status, best overall response, tumor PD-L1 expression, and PD-(L)1 blockade-based ICI therapy type (PD-(L)1 blockade alone; PD-(L)1 blockade with either CTLA-4 or chemotherapy) are indicated. PFS is shown in months, where asterisks signify ongoing responses. TMB is presented as the number of nonsynonymous mutations per megabase of the coding exome captured, measured in the blood (See Figure S2A–B). Mutations in the most recurrently mutated genes in TCGA NSCLC cases that also overlapped the NSCLC-focused CAPP-Seq selector in our cohort are shown at the bottom. See also Figure S4.